These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 15122511)
1. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. CHEK2 Breast Cancer Case-Control Consortium Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511 [TBL] [Abstract][Full Text] [Related]
2. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases. Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889 [TBL] [Abstract][Full Text] [Related]
3. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774 [TBL] [Abstract][Full Text] [Related]
4. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502 [TBL] [Abstract][Full Text] [Related]
5. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. Yang Y; Zhang F; Wang Y; Liu SC Asian Pac J Cancer Prev; 2012; 13(7):3501-5. PubMed ID: 22994785 [TBL] [Abstract][Full Text] [Related]
6. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948 [TBL] [Abstract][Full Text] [Related]
7. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190 [TBL] [Abstract][Full Text] [Related]
8. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry. Bernstein JL; Teraoka SN; John EM; Andrulis IL; Knight JA; Lapinski R; Olson ER; Wolitzer AL; Seminara D; Whittemore AS; Concannon P Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):348-52. PubMed ID: 16492927 [TBL] [Abstract][Full Text] [Related]
9. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. Näslund-Koch C; Nordestgaard BG; Bojesen SE J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562 [TBL] [Abstract][Full Text] [Related]
10. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877 [TBL] [Abstract][Full Text] [Related]
11. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342 [TBL] [Abstract][Full Text] [Related]
12. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation. Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852 [TBL] [Abstract][Full Text] [Related]
13. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844 [TBL] [Abstract][Full Text] [Related]
14. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969 [TBL] [Abstract][Full Text] [Related]
15. Increased risk of breast cancer associated with CHEK2*1100delC. Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452 [TBL] [Abstract][Full Text] [Related]
16. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328 [TBL] [Abstract][Full Text] [Related]
17. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. Offit K; Pierce H; Kirchhoff T; Kolachana P; Rapaport B; Gregersen P; Johnson S; Yossepowitch O; Huang H; Satagopan J; Robson M; Scheuer L; Nafa K; Ellis N BMC Med Genet; 2003 Jan; 4():1. PubMed ID: 12529183 [TBL] [Abstract][Full Text] [Related]
18. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428 [TBL] [Abstract][Full Text] [Related]
19. CHEK2 1100delC is not a risk factor for male breast cancer population. Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717 [TBL] [Abstract][Full Text] [Related]